

**IN THE UNITED STATES BANKRUPTCY COURT
FOR THE DISTRICT OF DELAWARE**

In re:

HUMANIGEN, INC.,¹

Debtor.

Chapter 11

Case No. 24-10003 (BLS)

**AMENDED GLOBAL NOTES
AND STATEMENT OF LIMITATIONS AND METHODOLOGY
REGARDING THE DEBTOR'S AMENDED SCHEDULES OF ASSETS AND
LIABILITIES AND AMENDED STATEMENTS OF FINANCIAL AFFAIRS**

The above-captioned debtor and debtor in possession (the "Debtor") is filing its respective amended Schedules of Assets and Liabilities (collectively, the "Schedules") and amended Statements of Financial Affairs (collectively, the "Statements," and together with the Schedules, the "Schedules and Statements") in the United States Bankruptcy Court for the District of Delaware (the "Court"). These Schedules and Statements amend and supersede any previously filed Schedules of Assets and Liabilities and Statements of Financial Affairs in their entirety. The Debtor, with the assistance of its professional advisors, prepared the Schedules and Statements in accordance with section 521 of title 11 of the United States Code, 11 U.S.C. §§ 101–1532 (the "Bankruptcy Code"), Rule 1007 of the Federal Rules of Bankruptcy Procedure (the "Bankruptcy Rules"), and Rule 1007-1 of the Local Rules of Bankruptcy Practice and Procedure of the United States Bankruptcy Court for the District of Delaware (the "Local Rules").

These Global Notes and Statement of Limitations and Methodology Regarding the Debtor's Schedules and Statements (the "Global Notes") comprise an integral part of the Schedules and Statements and should be referred to and considered in connection with any review of the Schedules and Statements.

The Debtor used commercially reasonable efforts to ensure the accuracy and completeness of the information and data used in preparing the Schedules and Statements. Inadvertent errors, omissions, or inaccuracies may exist in the Schedules and Statements. The Debtor and its estate reserve all rights to amend or supplement the Schedules and Statements as may be necessary and appropriate. Nothing contained in the Schedules and Statements or these Global Notes shall constitute a waiver of the Debtor's rights or an admission with respect to its chapter 11 case, including any issues involving objections to claims, equitable subordination, defenses, characterization or re-characterization of contracts and leases, assumption or rejection of contracts and leases under the provisions of chapter 3 of the Bankruptcy Code, causes of action arising under

¹ The Debtor's mailing address in this chapter 11 case is 533 Airport Boulevard, Suite 400, Burlingame, CA 94010 and the last four digits of the Debtor's federal tax identification number are 7236.

the provisions of chapter 5 of the Bankruptcy Code, or any other relevant or applicable laws to recover assets or avoid transfers.

I. Notes Applicable to all Schedules and Statements

Note 1: Reporting Date. Although the petition date was January 3, 2024 (the “Petition Date”), all asset and liability information, except where otherwise noted, is provided as of the close of business on December 31, 2023.

Note 2: Currency. Unless otherwise indicated, all amounts are reflected in U.S. dollars. To the extent any amounts had to be converted to U.S. dollars, the conversion rate used was as of December 31, 2023 except for a few foreign payables that were valued at the invoice date.

Note 3: Signatory. Henry Madrid has signed each set of Schedules and Statements. Mr. Madrid serves as Senior Vice President of Finance of Humanigen, Inc.. In reviewing and signing the Schedules and Statements, Mr. Madrid has necessarily relied upon the efforts, statements, advice, and representations of personnel of the Debtor and its legal advisors. Mr. Madrid has not personally verified and could not personally verify the accuracy of each such statement and representation, but believes them to be true, correct, and accurate as of the date he signed the Schedules and Statements.

Note 4: Basis of Presentation. The Schedules and Statements do not purport to represent financial statements prepared in accordance with Generally Accepted Accounting Principles in the United States (“GAAP”), nor are they intended to be fully reconciled to the financial statements of each Debtor. The Schedules and Statements contain unaudited information that is subject to further review and potential adjustment. The Schedules and Statements reflect the Debtor’s reasonable efforts to report the assets and liabilities of each Debtor on an unconsolidated basis. These Schedules and Statements were not filed with the United States Securities and Exchange Commission (the “SEC”) or any other authority, and neither the SEC nor any state authority has passed upon the accuracy or adequacy of the Schedules and Statements, or upon the merits of the Schedules and Statements.

Note 5: Net Book Value. In certain instances, current market valuations for individual items of property and other assets are neither maintained by nor readily available to the Debtor. Accordingly, unless otherwise indicated, the Schedules and Statements reflect net book values as of December 31, 2023.

Note 6: Estimates and Assumptions. The preparation of the Schedules and Statements required the Debtor to make reasonable estimates and assumptions with respect to the reported amounts of assets and liabilities, the amount of contingent assets and contingent liabilities on the date of the Schedules and Statements, and the reported amounts of revenues and expenses during the applicable reporting periods. Actual results could differ from such estimates.

Note 7: Totals. All totals that are included in the Schedules and Statements represent totals of all known amounts. To the extent there are undetermined amounts, the actual total may be different from the listed total.

Note 8: Confidential Information. There are instances in the Schedules and Statements where

the Debtor deemed it necessary and appropriate to redact from the public record information such as addresses or amounts. The redactions are limited to only what is necessary to protect the Debtor or the applicable third party. This approach is consistent with the relief requested by the Debtor in the *Motion of Debtor for Entry of Interim and Final Orders (I) Authorizing the Debtor to Redact Certain Personally Identifiable Information and (II) Granting Related Relief* [Docket No. 5] (the “Redaction Motion”) which was granted on an interim basis on January 8, 2024 pursuant to the *Interim Order (I) Authorizing the Debtor to Redact Certain Personally Identifiable Information and (II) Granting Related Relief* [Docket No. 25] and on a final basis on January 29, 2024 pursuant to the *Final Order (I) Authorizing the Debtor to Redact Certain Personally Identifiable Information and (II) Granting Related Relief* [Docket No. 74].

Note 9: Causes of Action. Despite their reasonable efforts to identify all known assets, the Debtor may not have listed all of its causes of action or potential causes of action against third parties as assets in its Schedules and Statements, including, without limitation, avoidance actions arising under chapter 5 of the Bankruptcy Code and actions under other relevant bankruptcy and non-bankruptcy laws to recover assets. The Debtor reserves all of its rights with respect to any cause of action (including avoidance actions), controversy, right of setoff, cross claim, counterclaim, or recoupment, and any claim on contracts or for breaches of duties imposed by law or in equity, demand, right, action, lien, indemnity, guaranty, suit, obligation, liability, damage, judgment, account, defense, power, privilege, license, and franchise of any kind or character whatsoever, known, unknown, fixed or contingent, matured or unmatured, suspected or unsuspected, liquidated or unliquidated, disputed or undisputed, secured or unsecured, assertable directly or derivatively, whether arising before, on, or after the Petition Date, in contract or in tort, in law or in equity, or pursuant to any other theory of law (collectively, “Causes of Action”) it may have, and neither these Global Notes nor the Schedules and Statements shall be deemed a waiver of any claims or Causes of Action, or in any way prejudice or impair the assertion of such claims or Causes of Action.

Note 10: Claim Designation. Any failure to designate a claim in the Schedules and Statements as “contingent,” “unliquidated,” or “disputed” does not constitute an admission by the Debtor that such claim or amount is not “contingent,” “unliquidated,” or “disputed.” The Debtor reserves all of its rights to dispute, or to assert offsets or defenses to, any claim reflected on their Schedules or Statements on any grounds, including, but not limited to, amount, liability, priority, status, or classification, or to otherwise subsequently designate any claim as “contingent,” “unliquidated,” or “disputed.” Moreover, the Debtor reserves all of its rights to amend its Schedules and Statements as necessary and appropriate. Listing a claim does not constitute an admission of liability by the Debtor.

Note 11: Fiscal Year. The Debtor’s fiscal year ends on or about December 31, 2023.

Note 12: Property and Equipment. Unless otherwise indicated, owned property and equipment are stated at net book value. The Debtor may lease furniture, fixtures, and equipment from certain third party lessors. Any such leases are set forth in the Schedules and Statements. Nothing in the Schedules and Statements is or shall be construed as an admission as to the determination as to the legal status of any lease (including whether any lease is a true lease or a financing arrangement), and the Debtor reserves all of its rights with respect to same.

Note 13: Unliquidated Claim Amounts. Claim amounts that could not be readily quantified by the Debtor is scheduled as “unliquidated.”

Note 14: Undetermined Amounts. The description of an amount as “undetermined” is not intended to reflect upon the materiality of such amount.

Note 15: Credits and Adjustments. The claims of individual creditors for, among other things, goods, products, services, or taxes are listed as the amounts entered on the Debtor’s books and records and may not reflect credits, allowances, or other adjustments due from such creditors to the Debtor. In the ordinary course of business, the Debtor regularly incurs credits and debits that need to be balanced and, notwithstanding that credits might not be identified in the schedules or statements, the Debtor is not waiving them. The Debtor reserves all of its rights with regard to such credits, allowances, and other adjustments, including the right to assert claims objections and/or setoffs with respect to the same.

Note 16: Insiders. In circumstances where the Schedules and Statements require information regarding “insiders”, the Debtor has included information with respect to the individuals and entities that the Debtor believes may be included in the definition of “insider” set forth in section 101(31) of the Bankruptcy Code during the relevant time periods. Such individuals may no longer serve in such capacities. Persons and entities listed as “insiders” have been included for informational purposes only. The Debtor does not take any position with respect to (a) such person’s influence over the control of the Debtor; (b) the management responsibilities or functions of such individual; (c) the decision-making or corporate authority of such individual; or (d) whether such individual could successfully argue that he or she is not an “insider” under applicable law, including the federal securities law, or with respect to any theories of liability or any other purpose. As such, the Debtor reserves all rights to dispute whether someone identified in response to Question 4 is in fact an “insider” as defined in section 101(31) of the Bankruptcy Code.

Note 17: Payments. Prior to the Petition Date, the Debtor maintained a cash management and disbursement system in the ordinary course of their business (the “Cash Management System”) (as described in the *Motion of Debtor for Entry of Interim and Final Orders Authorizing (I) Continued Use of Existing Cash Management System, Including Maintenance of Existing Bank Accounts, Checks, and Business Forms, and (II) Continuation of Existing Deposit Practices* [Docket No. 4] (the “Cash Management Motion”). Although efforts have been made to attribute open payable amounts to the correct legal entity, the Debtor reserves the right to further modify or amend its Schedules and Statements to attribute such payment to a different legal entity, if appropriate. The Debtor has authority to pay certain outstanding prepetition claims pursuant to bankruptcy court orders, including certain orders entered in connection with the Debtor’s chapter 11 case authorizing the Debtor to pay certain prepetition claims. If any such claims or liabilities have been satisfied, they may not be listed on the Schedules and Statements. If the Debtor has reached any postpetition settlement with a vendor or other creditor, the terms of such settlement will prevail, supersede amounts listed in the Schedules and Statements, and shall be enforceable.

Note 18: Reservation of Rights. In preparing the Schedules and Statements, the Debtor relied on unaudited financial data derived from its books and records that was available at the time of their preparation. Although the Debtor has made every reasonable effort to ensure the accuracy and completeness of the Schedules and Statements, inadvertent errors or omissions might exist and

subsequent information or discovery might result in material changes or modification to the Schedules and Statements that require the Debtor to file further amended Schedules and Statements. **The Debtor reserves all of its rights under Bankruptcy Rule 1009 to amend or modify any of the Schedules and Statements, including with respect to the treatment, characterization, classification, amount, omission, or inclusion of any claims, assets, liabilities, or executory contracts, and to the extent necessary to advance positions in the chapter 11 case that might conflict with the Schedules and Statements. Nothing contained in the Schedules and Statements or these Global Notes shall constitute a waiver of rights with respect to this chapter 11 case, including the following:**

- a. Any failure to designate a claim listed on the Schedules and Statements as “disputed,” “contingent,” or “unliquidated” does not constitute an admission by the Debtor that such amount is not “disputed,” “contingent,” or “unliquidated.” The Debtor reserves the right to dispute and to assert setoff rights, counterclaims, and defenses to any claim reflected on the Schedules as to amount, liability, and classification, and to otherwise subsequently designate any claim as “disputed,” “contingent,” or “unliquidated.”
- b. Notwithstanding that the Debtor has made reasonable efforts to correctly characterize, classify, categorize, or designate certain claims, assets, executory contracts, unexpired leases, and other items reported in the Schedules and Statements, the Debtor nonetheless may have improperly characterized, classified, categorized, or designated certain items. The Debtor thus reserves all rights to recharacterize, reclassify, recategorize, or redesignate items reported in the Schedules and Statements at a later time as is necessary and appropriate.
- c. The listing of a claim or agreement (i) on Schedule D as “secured,” (ii) on Schedule E/F (Part 1) as “priority,” (iii) on Schedule E/F (Part 2) as “unsecured,” or (iv) on Schedule G as “executory” or “unexpired” does not constitute an admission by the Debtor of the legal rights of the claimant, the executory nature of the agreement under section 365 of the Bankruptcy Code, or a waiver of the Debtor’s rights to recharacterize or reclassify such claim or agreement pursuant to a schedule amendment, claim objection or otherwise. Moreover, although the Debtor may have scheduled claims of various creditors as secured claims for informational purposes, no current valuation of the Debtor’s assets in which such creditors may have a security interest has been undertaken. Except as provided in an order of the Bankruptcy Court, the Debtor reserves all rights to dispute and challenge the secured nature or amount of any such creditor’s claims or the characterization of the structure of any transaction, or any document or instrument related to such creditor’s claim.
- d. The claims of individual creditors for, among other things, goods, products, services or taxes are listed as the amounts entered on the Debtor’s books and records and may not reflect credits, allowances or other adjustments due

from such creditors to the Debtor. The Debtor reserves all rights with regard to such credits, allowances and other adjustments, including the right to assert claims objections or setoffs with respect to the same.

- e. Although the Debtor has exercised reasonable efforts to ensure the accuracy of the Schedules and Statements, they nevertheless may contain errors and omissions. The Debtor hereby reserves all rights to dispute the validity, status, and enforceability of any contracts, agreements, and leases identified in the Schedules and Statements, and to further amend and supplement the Schedules and Statements as necessary.
- f. The Debtor further reserves all rights, claims, and causes of action with respect to the contracts and agreements listed on the Schedules and Statements, including the right to dispute and challenge the characterization or the structure of any transaction, document, and instrument related to a creditor's claim.
- g. The Debtor exercised reasonable efforts to locate and identify guarantees and other secondary liability claims (the "Guarantees") in its executory contracts, unexpired leases, secured financings, debt instruments, and other agreements. If such Guarantees have been identified, they are included in the relevant Schedules and Statements. Guarantees embedded in the Debtor's executory contracts, unexpired leases, secured financings, debt instruments, and other agreements may have been omitted inadvertently. Thus, the Debtor reserves its rights to further amend and supplement the Schedules and Statements if additional Guarantees are identified. In addition, the Debtor reserves the right to amend the Schedules and Statements to recharacterize and reclassify any such contract or claim.
- h. Exclusion of certain intellectual property should not be construed to be an admission that such intellectual property rights have been abandoned, have been terminated or otherwise expired by their terms, or have been assigned or otherwise transferred pursuant to a sale, acquisition, or other transaction. Conversely, inclusion of certain intellectual property should not be construed as an admission that such intellectual property rights have not been abandoned, terminated or otherwise expired by their terms, or have not been assigned or otherwise transferred pursuant to a sale, acquisition, or other transaction.

III. Notes to Schedules of Assets and Liabilities

1. ***Schedule A/B – Assets.*** The Debtor has potentially excluded the assets of the Australian subsidiary. Other immaterial assets may also have been excluded. Unless otherwise noted, all amounts listed in Schedule A/B are as of December 31, 2023.

Schedule A/B, Part 1 – Cash. The cash and cash equivalents listed in the Schedules reflect values as of December 31, 2023. The Debtor's account held at Comerica identified as

“Restricted” is a restricted cash account (the “Restricted Account”). As of the Petition Date, the Restricted Account held cash collateral required to collateralize the Debtor’s corporate credit card program and certain annual export licensing fees.

Schedule A/B, Part 2 – Deposits, including security deposits and utility deposits. Deposit values provided for in Schedule A/B, Item 7 is the value listed in the Debtor’s books and records as of December 31, 2023.

Schedule A/B, Part 2 – Prepayments, Including Prepayments on Executory Contracts, Leases, Insurance, Taxes, and Rent. Prepayment values provided for in Schedule A/B, Item 8 are the net book value listed in the Debtor’s books and records as of December 31, 2023.

Schedule A/B, Part 5 – Inventory, Excluding Agricultural Assets. The Debtor has at various locations drug products considered research and development material. These materials were expensed when purchased. Therefore, the current value is listed as zero.

Schedule A/B, Part 10 – Intangibles and Intellectual Property. The current value of internet domain names and websites is listed as undetermined. The Debtor is not able to provide a schedule with values specific to the internet domain name and website. The consolidated net book value of such assets is \$20,201.50, as of December 31, 2023. Regarding patents, copyrights, trademarks, and trade secrets on the attached Schedule 1 to the Schedules, although the Debtor has made every reasonable effort to ensure the accuracy and completeness of Schedule 1, inadvertent errors or omissions might exist and the Debtor reserves its rights to further amend Schedule 1.

Schedule A/B, Part 11 – All Other Assets. Except where otherwise noted, the value of all assets listed on Schedule A/B are calculated as of December 31, 2023.

Notes Receivable. The Debtor has an intercompany receivable from its Australian subsidiary of \$2.4M AUD. The Debtor believes the current value of the intercompany receivable is zero because the Australian subsidiary has minimal assets and does not have the ability to repay the loan.

Tax Refunds and Unused Net Operating Losses (NOLs). At the time the Debtor’s NOLs were computed (December 31, 2023), the Debtor had \$171.4M of NOLs set to expire in the years of 2024 through 2037. The realization of these deferred taxes is dependent upon future earnings and the timing and amount are uncertain. Accordingly, they are fully reserved, and the current value is considered zero.

Causes of Action Against Third Parties (whether or not a lawsuit has been filed). The Debtor attempted to list known causes of action and other claims. Potential preference actions and/or fraudulent transfer action were not listed because the Debtor has not completed an analysis of such potential claims. The Debtors’ failure to list any cause of action, claim, or right of any nature is not an admission that such cause of action, claim, or right does not exist, and should not be construed as a waiver of such cause of action, claim, or right.

Other Contingent and Unliquidated Claims or Causes of Action of Every Nature, including Counterclaims of the Debtor and Rights to Setoff Claims. In the ordinary course of their business, the Debtor may have accrued, or may subsequently accrue, certain rights to counter-claims, cross-claims, setoffs, credits, rebates, or refunds with their customers, insurance agencies, or insurance carriers. If the Debtor becomes party to litigation, the Debtor may assert claims as a plaintiff or counterclaims and/or crossclaims as a defendant. Because such claims are unknown to the Debtor and not quantifiable as of the Petition Date, they are not listed on Schedule A/B, Part 11.

2. ***Schedule D – Creditors Who Have Claims Secured by Property.*** Except as specifically stated herein, the Debtor has not included parties that may believe their claims are secured through the holding of security deposits, that may be beneficiaries under a letter of credit, or that are secured through setoff rights, inchoate statutory lien rights, or other lien rights created by the laws of the jurisdictions in which the Debtor operates.
3. ***Schedule E/F – Creditors Who Have Unsecured Claims.*** Except where otherwise noted, the value of all unsecured liabilities listed on Schedule E/F are calculated as of December 31, 2023.

The Debtor allocated liabilities between the prepetition and postpetition periods based on the information and research conducted in connection with the preparation of the Schedules and Statements. Some of the scheduled liabilities are unknown, contingent and/or unliquidated at this time. In such cases, the amounts are listed as “Undetermined.” Accordingly, the Schedules and the Statements may not equal the aggregate value of the Debtor’s total liabilities as noted on any previously issued financial statements.

Detailed descriptions of the Debtor’s debt structure and descriptions are contained in the *Declaration of Henry Madrid, Senior Vice President of Finance of the Debtor, in Support of Chapter 11 Petition and First Day Pleadings* [Docket No. 7] (the “First Day Declaration”).

Paid Claims. The Debtor has authority to pay certain outstanding prepetition liabilities pursuant to the Bankruptcy Court’s first day orders (collectively, the “First Day Orders”). As such, certain liabilities listed in these Schedules and Statements may have been, or may be, subsequently reduced or satisfied pursuant to the First Day Orders notwithstanding the fact that the Debtor has listed claims and payables as of the Petition Date in these Schedules and Statements.

Excluded Liabilities. The Debtor has potentially excluded the following categories of liabilities from the Schedules and Statements: deferred tax liabilities; and certain accrued liabilities including salaries and employee benefits. The Debtor has also excluded potential Claims arising on account of the potential rejection of executory contracts and unexpired leases, to the extent such Claims exist. Other immaterial liabilities may also have been excluded.

Part 1 – Creditors with Priority Unsecured Claims. The Debtor does not list any claims on Schedule E/F, Part 1. Pursuant to the *Final Order Authorizing Payment of (I) Certain*

Prepetition Employee Claims, Including Wages, Salaries, and Other Compensation, (II) Certain Employee Benefits and Confirming Right to Continue Employee Benefits on Post-Petition Basis, (III) Reimbursement to Employees for Prepetition Expenses, (IV) Withholding and Payroll-Related Taxes, (V) Workers' Compensation Obligation, and (VI) Prepetition Claims Owing to Administrators and Third-Party Providers [Docket No. 75] (the "Employee Wage Order"), the Debtor received authority to pay certain prepetition obligations, including certain employee wages and other employee benefits in the ordinary course of business. The Debtor believes that (but cannot guarantee that) such claims will be satisfied in the ordinary course during the chapter 11 cases pursuant to the authority granted in the Employee Wage Order or other order that may be entered by the Bankruptcy Court. Additionally, claims against the Debtor on account of wage or wage-related obligations may maintain priority under section 507 of the Bankruptcy Code, but are subject to the priority cap imposed under subsections (a)(4) and (a)(5) of section 507 of the Bankruptcy Code.

Part 2 – Creditors with Nonpriority Unsecured Claims. The liabilities identified in Schedule E/F, Part 2, are derived from the Debtor's books and records. The Debtor made reasonable attempts to set forth their unsecured obligations, although the actual amount of claims against the Debtor may vary from those liabilities represented on Schedule E/F, Part 2. The listed liabilities may not reflect the correct amount of any unsecured creditor's allowed claims or the correct amount of all unsecured claims. The amounts listed on schedule E/F may not reflect any right of setoff or recoupment, and the Debtor reserves any such setoff or recoupment rights. Additionally, certain creditors may assert mechanics', materialmans', or other similar liens against the Debtor for amounts listed in Schedule E/F.

In many cases, the claims listed on Schedule E/F, Part 2, arose, accrued, or were incurred on various dates or on a date or dates that are unknown to the Debtor or are subject to dispute. Where the determination of the date on which a claim arose, accrued, or was incurred would be unduly burdensome and costly to the Debtor's estates, the Debtor has not listed a specific date or dates for such claim, or may have listed "various".

As of the time of filing of the Schedules and Statements, the Debtor may not have received all invoices for payables, expenses, and other liabilities that may have accrued prior to the Petition Date. Accordingly, the information contained in Schedules D and E/F may be incomplete. The Debtor reserves its rights to further amend Schedules D and E/F if, or when, the Debtor receives such invoices.

Trade Payables. The value of trade payables is calculated as of December 31, 2023. To the extent that goods were delivered under purchase orders prior to December 31, 2023, vendors' claims with respect to such delivered goods are included on Schedule E/F.

4. **Schedule G – Executory Contracts and Unexpired Leases.** Although the Debtor has made reasonable efforts to attribute an executory contract or unexpired lease on Schedule G, in certain instances, the Debtor may have inadvertently failed to do so due to the complexity of the Debtor's business. The Debtor reserves all of its rights with respect to the named

parties of any and all executory contracts and unexpired leases, including the right to further amend, supplement, or otherwise modify Schedule G.

Certain of the executory contracts and unexpired leases listed on Schedule G may contain certain renewal options, guarantees of payment, options to purchase, rights of first refusal, right to lease additional space, and other miscellaneous rights. These rights, powers, duties, and obligations are not set forth separately on Schedule G. To the extent that such documents constitute executory contracts, the documents may have been omitted.

In the ordinary course of business, the Debtor has entered into numerous contracts or agreements, some of which may be oral. While the Debtor has made every effort to reflect the current agreements, to the extent such contracts or agreements constitute executory contracts, certain of these contracts and agreements may not be listed individually on Schedule G.

The Debtor reserves all rights to dispute or challenge the characterization of any transaction or any contract, agreement, document or other instrument related to a creditor's claim. Further, the designation of a category is not meant to be wholly inclusive or descriptive of the entirety of the rights or obligations represented by such contract. The contracts, agreements, and leases listed on Schedule G may have expired or may have been modified, amended, or supplemented from time to time by various amendments, restatements, waivers, estoppel certificates, letters, memoranda, and other documents, instruments and agreements that may not be listed therein despite the Debtor's use of reasonable efforts to identify such documents. Further, unless otherwise specified on Schedule G, each executory contract or unexpired lease listed thereon shall include all exhibits, schedules, riders, modifications, declarations, amendments, supplements, attachments, restatements, or other agreements made directly or indirectly by any agreements, instruments, or other document that in any manner affects such executory contract or unexpired lease, without respect to whether such agreement, instrument, or other document is listed thereon.

In some cases, the same supplier or provider may appear multiple times in Schedule G. Multiple listings, if any, reflect distinct agreements between the applicable Debtor and such supplier or provider. The listing of any contract on Schedule G does not constitute an admission by the Debtor as to the validity of any such contract. The Debtor reserves the right to dispute the effectiveness of any such contract listed on Schedule G or whether any contract listed on Schedule G is an executory contract or to amend Schedule G at any time to remove any contract.

The Debtor has exercised reasonable efforts to locate and identify guarantees of their executory contracts, unexpired leases, secured financings, and other such agreements. Where guarantees have been identified, they have been included in the relevant Schedules G.

III. Notes to Statements of Financial Affairs

1. ***Statements, Part 1, Questions 1 and 2 – Income and Non-business Revenue.*** Revenue has been provided through December 31, 2023.
2. ***Statements, Part 2, Questions 3 and 4 – Payments to Certain Creditors.*** The Debtor operates an integrated system of bank accounts to facilitate the collection and disbursement of funds as part of the Cash Management System. The Debtor's responses to Questions 3 and 4 on each of the Debtor's Statements reflect payments made by the Debtor from bank accounts on behalf of the Debtor, pursuant to the Debtor's Cash Management System described in the Cash Management Motion.

For the purposes of these Statements, the Debtor used December 31, 2023 as the date of the information for the financial information provided. The Debtor has responded to Question 3 in detailed format by listing each payment. The response to Question 3, however, does not include transfers to bankruptcy professionals (which transfers appear in response to Part 6, Question 11).

The payroll-related amount shown in response to Question 4, which includes, among other things, salary, wage, and additional compensation, is a gross amount that does not include reductions for amounts including employee tax or benefit withholdings.

3. ***Statements, Part 3, Question 7*** – The Debtor has used reasonable efforts to report all legal actions, proceedings, investigations, arbitrations, mediations, and audits by federal or state agencies in which the Debtor was involved in any capacity within one year before the Petition Date. The Debtor reserves all rights to assert that it is not an appropriate party to such actions or proceedings. For the avoidance of doubt, the Debtor has excluded actions relating to workers' compensation claims, if any, from Statement 7.
4. ***Statements, Part 6, Question 11 – Payments Related to Bankruptcy.*** Presented herein are payments made to various professional services firms for services rendered within one year immediately preceding the Petition Date. The services rendered pertain to (i) the Debtor's 2023 prepetition sale and marketing process, (ii) relief under the Bankruptcy Code, and (iii) preparation of a bankruptcy petition. Amounts listed reflect the total amounts paid to these respective firms, as bifurcating the specific restructuring activities would be administratively burdensome.

Information regarding the Debtor's retention of professional service firms is more fully described in the individual retention applications and related orders.

5. ***Statements, Part 13, Question 26 – Books, Records, and Financial Statements.***

The Debtor has supplied financial statements and reports in the ordinary course of business to certain third parties under confidentiality agreements. Such third parties include former officers and administrative agents of the Debtor's business. Therefore, the Debtor has not provided full lists of these parties in their response to Statement Question 26d.

6. ***Statements, Part 13, Question 28 – Debtor’s Officers, Directors, Managing Members, General Partners, Members in Control, Controlling Shareholders, or Other People in Control of the Debtor at the Time of the Filing of this Case.***

The Debtor has listed its majority equity holder in response to Question 28. Other equity holders have only nominal equity interests in the Debtor.

* * * * *

Fill in this information to identify the case:

Debtor name Humanigen, Inc.

United States Bankruptcy Court for the: DISTRICT OF DELAWARE

Case number (if known) 24-10003 (BLS)

Check if this is an amended filing

Official Form 206A/B
Schedule A/B: Assets - Real and Personal Property

12/15

Disclose all property, real and personal, which the debtor owns or in which the debtor has any other legal, equitable, or future interest. Include all property in which the debtor holds rights and powers exercisable for the debtor's own benefit. Also include assets and properties which have no book value, such as fully depreciated assets or assets that were not capitalized. In Schedule A/B, list any executory contracts or unexpired leases. Also list them on *Schedule G: Executory Contracts and Unexpired Leases* (Official Form 206G).

Be as complete and accurate as possible. If more space is needed, attach a separate sheet to this form. At the top of any pages added, write the debtor's name and case number (if known). Also identify the form and line number to which the additional information applies. If an additional sheet is attached, include the amounts from the attachment in the total for the pertinent part.

For Part 1 through Part 11, list each asset under the appropriate category or attach separate supporting schedules, such as a fixed asset schedule or depreciation schedule, that gives the details for each asset in a particular category. List each asset only once. In valuing the debtor's interest, do not deduct the value of secured claims. See the instructions to understand the terms used in this form.

Part 1: Cash and cash equivalents

1. Does the debtor have any cash or cash equivalents?

- No. Go to Part 2.
- Yes Fill in the information below.

All cash or cash equivalents owned or controlled by the debtor			Current value of debtor's interest
3.	Checking, savings, money market, or financial brokerage accounts <i>(Identify all)</i>		
	Name of institution (bank or brokerage firm)	Type of account	Last 4 digits of account number
3.1.	<u>Comerica Bank</u>	<u>Checking</u>	<u>5328</u>
			<u>\$67,665.38</u>
3.2.	<u>Comerica Bank</u>	<u>MMA (\$70,000 Restricted)</u>	<u>5336</u>
			<u>\$70,962.03</u>

4. **Other cash equivalents** *(Identify all)*

5. **Total of Part 1.**

Add lines 2 through 4 (including amounts on any additional sheets). Copy the total to line 80.

\$138,627.41

Part 2: Deposits and Prepayments

6. Does the debtor have any deposits or prepayments?

- No. Go to Part 3.
- Yes Fill in the information below.

7. **Deposits, including security deposits and utility deposits**
 Description, including name of holder of deposit

7.1. Bay Area Executive Offices Security Deposit \$1,391.00

8. **Prepayments, including prepayments on executory contracts, leases, insurance, taxes, and rent**

Debtor	Name	Case number (if known)	24-10003 (BLS)
	Description, including name of holder of prepayment		
8.1.	Mimecast annual subscription (email security)		\$498.87
8.2.	State of Delaware; overpayment of 2022 taxes less 2023 taxes owed; this was refunded in January 2024		\$69,710.00
8.3.	Intact Services USA LLC Multi Peril renewal		\$1,638.50
8.4.	Lockton - Excess D&O D77325221ASP		\$42,845.80
8.5.	Lockton - Employment Related Practices Liability 596681694		\$2,833.30
8.6.	Lockton - Fiduciary Liability 596681680		\$1,166.70
8.7.	Lockton - D&O ELU18104522		\$87,500.00
8.8.	Lockton - Excess D&O ELU18104722		\$16,666.70
8.9.	Lockton - Excess D&O OSIC403DOX120221		\$40,488.40
8.10.	General Liability - Commercial 2/20/2023 - 2/20/2024		\$6,878.70
8.11.	Cyber/Network Liability 02/20/2023 - 02/20/2024		\$411.95
8.12.	Cargo 2/20/2023- 2/20/2024 (Quarterly installments)		\$42,875.00
8.13.	Catalent Pharma Solutions - GALA (Madison); annual license		\$8,330.30
8.14.	Uppsala Monitoring Centre; annual subscription		\$1,850.08

Debtor Humanigen, Inc. Case number (if known) 24-10003 (BLS)
Name

8.15 Shook, Hardy & Bacon L.L.P (litigation retainer) \$20,000.00

8.16 Stichting EuroQol Research Foundation (License for EQ-5D-3L) \$3,024.18

9. **Total of Part 2.** **\$348,109.48**
 Add lines 7 through 8. Copy the total to line 81.

Part 3: Accounts receivable

10. Does the debtor have any accounts receivable?

- No. Go to Part 4.
- Yes Fill in the information below.

Part 4: Investments

13. Does the debtor own any investments?

- No. Go to Part 5.
- Yes Fill in the information below.

Part 5: Inventory, excluding agriculture assets

18. Does the debtor own any inventory (excluding agriculture assets)?

- No. Go to Part 6.
- Yes Fill in the information below.

Part 6: Farming and fishing-related assets (other than titled motor vehicles and land)

27. Does the debtor own or lease any farming and fishing-related assets (other than titled motor vehicles and land)?

- No. Go to Part 7.
- Yes Fill in the information below.

Part 7: Office furniture, fixtures, and equipment; and collectibles

38. Does the debtor own or lease any office furniture, fixtures, equipment, or collectibles?

- No. Go to Part 8.
- Yes Fill in the information below.

Part 8: Machinery, equipment, and vehicles

46. Does the debtor own or lease any machinery, equipment, or vehicles?

- No. Go to Part 9.
- Yes Fill in the information below.

Part 9: Real property

54. Does the debtor own or lease any real property?

- No. Go to Part 10.
- Yes Fill in the information below.

Debtor Humanigen, Inc.
Name

Case number (if known) 24-10003 (BLS)

Part 10: Intangibles and intellectual property

59. Does the debtor have any interests in intangibles or intellectual property?

- No. Go to Part 11.
 Yes Fill in the information below.

	General description	Net book value of debtor's interest (Where available)	Valuation method used for current value	Current value of debtor's interest
60.	Patents, copyrights, trademarks, and trade secrets See attached schedule 1.	\$0.00	None	Unknown
61.	Internet domain names and websites Lenzilumab.com	\$20,201.50	Purchase Price	Unknown

62. Licenses, franchises, and royalties
 63. Customer lists, mailing lists, or other compilations
 64. Other intangibles, or intellectual property
 65. Goodwill

66. Total of Part 10. \$0.00
 Add lines 60 through 65. Copy the total to line 89.

67. Do your lists or records include personally identifiable information of customers (as defined in 11 U.S.C. §§ 101(41A) and 107)?
 No
 Yes

68. Is there an amortization or other similar schedule available for any of the property listed in Part 10?
 No
 Yes

69. Has any of the property listed in Part 10 been appraised by a professional within the last year?
 No
 Yes

Part 11: All other assets

70. Does the debtor own any other assets that have not yet been reported on this form?
 Include all interests in executory contracts and unexpired leases not previously reported on this form.

- No. Go to Part 12.
 Yes Fill in the information below.

				Current value of debtor's interest
71.	Notes receivable Description (include name of obligor) Humanigen Australia Pty Ltd. (currency in AUD)	2,400,000.00 Total face amount	- 2,400,000.00 doubtful or uncollectible amount	= \$0.00

72. Tax refunds and unused net operating losses (NOLs)

24-10003 (BLS)

Debtor Humanigen, Inc.
Name

Case number (if known) _____

Description (for example, federal, state, local)

Fully reserved NOLs Tax year Several \$0.00

73. **Interests in insurance policies or annuities**

74. **Causes of action against third parties (whether or not a lawsuit has been filed)**

Patheon Biologics, Inc. v. Humanigen, Inc. \$0.00

Nature of claim Dispute of defective parts provided to Debtor

Amount requested \$37,500,000.00

75. **Other contingent and unliquidated claims or causes of action of every nature, including counterclaims of the debtor and rights to set off claims**

A 28% membership interest in the settlement of Madison Joint Venture LLC v. Chemo Research SL et. al., (Case No. 2:19-cv-08012)

Nature of claim Action for Damages \$0.00

Amount requested \$0.00

76. **Trusts, equitable or future interests in property**

77. **Other property of any kind not already listed** *Examples: Season tickets, country club membership*

78. **Total of Part 11.**

Add lines 71 through 77. Copy the total to line 90.

<u>\$0.00</u>

79. **Has any of the property listed in Part 11 been appraised by a professional within the last year?**

No

Yes

Debtor Humanigen, Inc.
Name

Case number (if known) 24-10003 (BLS)

Part 12: Summary

In Part 12 copy all of the totals from the earlier parts of the form

Type of property	Current value of personal property	Current value of real property
80. Cash, cash equivalents, and financial assets. <i>Copy line 5, Part 1</i>	<u>\$138,627.41</u>	
81. Deposits and prepayments. <i>Copy line 9, Part 2.</i>	<u>\$348,109.48</u>	
82. Accounts receivable. <i>Copy line 12, Part 3.</i>	<u>\$0.00</u>	
83. Investments. <i>Copy line 17, Part 4.</i>	<u>\$0.00</u>	
84. Inventory. <i>Copy line 23, Part 5.</i>	<u>\$0.00</u>	
85. Farming and fishing-related assets. <i>Copy line 33, Part 6.</i>	<u>\$0.00</u>	
86. Office furniture, fixtures, and equipment; and collectibles. <i>Copy line 43, Part 7.</i>	<u>\$0.00</u>	
87. Machinery, equipment, and vehicles. <i>Copy line 51, Part 8.</i>	<u>\$0.00</u>	
88. Real property. <i>Copy line 56, Part 9.....></i>		<u>\$0.00</u>
89. Intangibles and intellectual property. <i>Copy line 66, Part 10.</i>	<u>\$0.00</u>	
90. All other assets. <i>Copy line 78, Part 11.</i>	+ <u>\$0.00</u>	
91. Total. Add lines 80 through 90 for each column	<u>\$486,736.89</u>	+ 91b. <u>\$0.00</u>
92. Total of all property on Schedule A/B. Add lines 91a+91b=92		<u>\$486,736.89</u>

SCHEDULE 1

Country	Application No.	Patent No.	Application Status	Title
Australia	2005306502	2005306502	Registered	Immunoglobulin Variable Region Cassette Exchange
Canada	2587158	2587158	Registered	Immunoglobulin Variable Region Cassette Exchange
Europe	100141282	2343380 (Jun. 12, 2019)	Registered and validated in 19 countries: Austria, Belgium, Switzerland, Germany, Denmark, Spain, Finland, France, United Kingdom, Greece, Ireland, Italy, Luxembourg, Monaco, Netherlands, Poland, Portugal, Sweden and Turkey	Immunoglobulin Variable Region Cassette Exchange
United States	14/968,709 (Continuation of 11/282,107 filed 16-Nov-2005)	10,919,983 (Feb. 16, 2021)	Registered	Immunoglobulin Variable Region Cassette Exchange
Europe	19169135 (Divisional of EP 100141282 [P-566445-EP1])	3540062 (12 May 2021)	Registered and validated in 19 countries: Austria, Belgium, Switzerland, Germany, Denmark, Spain, Finland, France, United Kingdom, Greece, Ireland, Italy, Luxembourg, Monaco, Netherlands, Poland, Portugal, Sweden and Turkey.	Immunoglobulin Variable Region Cassette Exchange

Country	Application No.	Patent No.	Status	Title
Australia	2009243184	2009243184	Registered	Antibodies To Granulocyte-Macrophage Colony-Stimulating Factor
Canada	2722137	2,722,137	Registered	
China	2009801184230	CN102037016	Registered	
Europe	09739607.1	2280732	Registered and validated in 15 countries: UK, France, Germany, Switzerland, Austria, Italy, Spain, Belgium, the Netherlands, Luxembourg, Denmark, Sweden, Norway, Finland and Iceland.	
Europe	18200356.6 (Divisional of 09739607.1 [P-566450-EP4])	N/A	Pending	
Hong Kong	111024551	HK1148222	Registered	
Hong Kong	19126800.2	N/A	Pending	
Israel	208980	208980	Registered	
Japan	2011507586	5688363	Registered	
Korea	10-2010-7026423	10-1824512	Registered	
Korea	10-2017-7023943	10-1852915	Registered	
Mexico	MX/a/2010/011761	313002	Registered	
New Zealand	588850	588850	Registered	
Singapore	2010077303	165836	Registered	

Country	Application No.	Patent No.	Status	Title
South Africa	201008028	2010/08028	Registered	
United States	12/431,661 (not based on PCT)	8,168,183	Registered	
United States	13/460,151 (not based on PCT)	9,017,674	Registered	

Country	Application No./ Filing Date	Patent No.	Status	Title
United States	16/652,977 01-Apr-2020	11,673,962	Registered	Methods Of Treating Immunotherapy-Related Toxicity Using A Gm-Csf Antagonist
Europe	18865158.2	N/A	Pending	
Australia	2018345751	N/A	Pending	
Canada	3,078,349	N/A	Pending	
Japan	2020-520060	7320498	Registered	
Singapore	11202003096U	N/A	Pending	
China	201880073017.6	N/A	Pending	
New Zealand	763535	N/A	Pending	
Hong Kong	62020015177.2	N/A	Pending	
United States	16/149,346 02-Oct-18 (same specification & claims filed as in P-566450-PC11)	10,870,703 Issued on Dec. 22, 2020	Registered	Methods Of Treating Immunotherapy-Related Toxicity Using A Gm-Csf Antagonist
United States	17/097,303 13-Nov-2020 (same specification as 16/149,346)	N/A	Pending	Methods Of Treating Immunotherapy-Related Toxicity Using A Gm-Csf Antagonist
United States	16/204,220 29-Nov-18	10,899,831 Issued on Jan. 26, 2021	Registered	Methods Of Treating Immunotherapy-Related Toxicity Using A Gm-Csf Antagonist
United States	17/151,154 16-Jan-2021	N/A	Pending	Methods Of Treating Immunotherapy-Related Toxicity Using A Gm-Csf Antagonist

Country	Application No./ Filing Date	Patent No.	Status	Title
United States	16/248,762 15-Jan-2019	10,927,168 Issued on Feb. 23, 2021	Registered	Methods Of Treating Immunotherapy-Related Toxicity Using A Gm-Csf Antagonist
United States	17/160,325 27-Jan-2021	N/A	Pending	Methods Of Treating Immunotherapy-Related Toxicity Using A Gm-Csf Antagonist
United States	16/283,694 22-Feb-2019	11,130,805 29-SEP-2021	Registered	Methods Of Treating Immunotherapy-Related Toxicity Using A Gm-Csf Antagonist
United States	17/378,629 16-JUL-2021	N/A	Pending	Methods Of Treating Immunotherapy-Related Toxicity Using A Gm-Csf Antagonist
Australia	2019340662 29-Mar-2021	N/A	Pending	Methods Of Treating Immunotherapy-Related Toxicity Using A Gm-Csf Antagonist
Canada	3,111,804 04-Mar-2021	N/A	Pending	
China	201980073595 4 May 7, 2021	N/A	Pending	
Europe	19860890.3 01-Apr-2021	N/A	Pending	
Hong Kong	62021037018.0 16-Aug-2021	N/A	Pending	
Israel	281243 03-Mar-2021	N/A	Pending	
Japan	2021-512883 8- Mar-2021	N/A	Pending	
Mexico	MX/a/2021/00 2856 10-Mar-2021	N/A	Pending	
Singapore	10202300755R 10-Sep -019	N/A	Pending	
New Zealand	774480 29 March 2021	N/A	Pending	
United States	17/274,167 05-Mar2021	N/A	Pending	
United States	17/234,779 19-Apr-2021	N/A	Pending	

Country	Application No./ Filing Date	Patent No.	Status	Title
United States	PCT/US22/25089 15-Apr-2022	N/A	Pending	
United States)	111114798 19 April 2022	N/A	Pending	

Country	Application No./ Filing Date	Patent No.	Status	Title
Australia	2019374102 31-Oct-2019 (NPE May 26, 2021)	N/A	Pending	Materials And Methods For Treating Cancer
Canada	3,116,412 31-Oct-2019 (NPE 13-Apr-2021)	N/A	Pending	
China	2019800726813 31-Oct-2019 (NPE 30-Apr-2021)	N/A	Pending	
Europe	19880756.2 31-Oct-2019 (RPE 18-May-2021)	N/A	Pending	
Hong Kong	62021038662.4 31-Oct-2019 (NPE 10-Sep-2021)	N/A	Pending	
Israel	282478 31-Oct-2019 (NPE 20-Apr-2021)	N/A	Pending	
Japan	2021-548569 31-Oct-2019 (NPE 28- Apr-2021)	N/A	Pending	
Mexico	MX/a/2021/ 004993 31-Oct-2019 (NPE 29- Apr-2021)	N/A	Pending	
New Zealand	776524 31-Oct-2019 (NPE May 26,2021)	N/A	Pending	
Singapore	10202301171T 31-Oct-2019 (DIV 27-APR-2023)	N/A	Pending	

United States	17/290,185 31-Oct-2019 (NPE 29-Apr-2021)	N/A	Pending	
United States	17/209,160 22-Mar-2021	N/A	Pending	Materials And Methods For Treating Cancer
United States	PCT/US22/20459 15-Mar-2022	N/A	Pending	Materials And Methods For Treating Cancer
United States	15-Mar-2022 18/283,196 National Phase Entry on September 20, 2023	N/A	Pending	Materials And Methods For Treating Cancer
United States		N/A	To be filed	

Country	Application No./ Filing Date	Patent No.	Status	Title
Australia	2021235899 08-Mar-2021	N/A	Pending	Methods For Treating/Preventing Coronavirus Infection And Resulting Inflammation-Induced Lung Injury
Brazil	BR 112022017891-3 08-Mar-2021	N/A	Pending	
Canada	3,173,970 08-Mar-2021	N/A	Pending	
China	202180032152.8 08-Mar-2021	N/A	Pending	
Europe	21767746.7 08-Mar-2021	N/A	Pending	
Europe	62023068043.6 08-Mar-2021	N/A	Not Examined	
Israel	296082 08-Mar-2021	N/A	Pending	
Japan	2022-554237 08-Mar-2021	N/A	Pending	
Korea	10-2022-7035029 08-Mar-2021	N/A	Pending	
Mexico	MX/a/2022/011111 08-Mar-2021	N/A	Pending	
New Zealand	792462 08-Mar-2021	N/A	Pending	
Singapore	11202252377V 08-Mar-2021	N/A	Pending	
United States	17/909,377 08-Mar-2021 (NPE 03-SEP-2022)	N/A	Pending	
United States	17/216,660 29-Mar-2021	N/A	Pending	
United States	17/306,884 03-May-2021	N/A	Pending	

Country	Application No./ Filing Date	Patent No.	Status	Title
				Coronavirus Infection And Resulting Inflammation-Induced Lung Injury
United States	PCT/US22/19028 04-Mar-2022	N/A	Pending	Methods For Treating/Preventing Coronavirus Infection And Resulting Inflammation-Induced Lung Injury
United States	18/280,642 04-Mar-2022 National Phase Entry on Sep. 6, 2023	N/A	Pending	
United States	ROC (Taiwan) Pat. Appln. No. 111108447 08-Mar-2022	N/A	Pending	

Country	Application No./ Filing Date	Patent No.	Status	Title
United States	63/452,147 Mar. 14, 2023	N/A	Pending	Combination Treatment Of Chronic Myelomonocytic Leukemia In Patients With Ras Pathway Mutations
United States		N/A	Likely filing	Combination Treatment Of Chronic Myelomonocytic Leukemia In Patients With Ras Pathway Mutations

Country	Application Nos	Patent No.	Status	Title
Australia	2008226905	2008226905	Registered	Epha3 Antibodies For The Treatment Of Solid Tumors
Canada	2,679,986	2,679,986	Registered	
China	20088000762 6.8	20088000762 6.8	Registered	
Europe	08726647.4	2136838	Registered (3) (Validated in Germany, France, and UK)	
Europe	17159714.9 (Divisional of 08726647.4 [P-566451-EP])	3199180	Registered Validated in 19 countries: Austria (AT), Belgium (BE), Switzerland (CH), Germany (DE), Denmark (DK), Spain (ES), Finland (FI), France (FR), United Kingdom (GB), Greece (GR), Ireland (IE), Italy (IT), Luxembourg (LU), Monaco (MC), Netherlands (NL), Poland (PL), Portugal (PT), Sweden (SE), and Turkey (TR)	
Hong Kong	181001531.4	HK1242185	Registered	
Japan	2009552761	5311060	Registered	

Country	Application Nos	Patent No.	Status	Title
United States	12/045,589	8,637,016	Registered	

Country	Application Nos	Patent No.	Status	Title
United States	12/718,768	8,834,870	Registered	Treatment of Leukemias and Chronic Myeloproliferative Diseases With Antibodies to Epha3

Country	Application No.	Patent No.	Status	Title
Australia	2010313621	2010313621	Registered	Antibodies To Epha3
Canada	2777068	2777068	Registered	
China	20108005661 8X	ZL 20108005661 8.X	Registered	
United States	12/904,953	8,664,365	Registered	
United States	14/143,427	9,290,571	Registered	
Europe	10777137	2488554	Registered (19) (Jul. 24, 2019) validated in 19 countries: Austria (AT), Belgium (BE), Switzerland (CH), Germany (DE), Denmark (D K), Spain (ES), Finland (FI), France (FR), United Kingdom (GB), Greece (GR), Ireland (IE), Italy (IT), Luxembourg (LU), Monaco (MC), Netherlands (NL), Poland (PL), Portugal (PT), Sweden (SE), and Turkey (TR)	Antibodies To Epha3

Country	Application No.	Patent No.	Status	Title
United States	13/571,827	9,109,032	Registered	Methods Of Treating Hematological Proliferative Disorders By Targeting Epha3 Expressed On Aberrant Vasculature In Bone Marrow

Country	Application No.	Patent No.	Status	Title
United States	13/480,937	9,045,539	Registered	Anti-EMR1 Antibodies

Country	Application No.	Patent No.	Status	Title
N/A Handled by Rimon Law, P.C.	10/330,811	8,148,110	Registered	Detection Of Molecular Interactions By Beta-Lactamase Reporter Fragment Complementation

Country	Application No./ Filing Date	Patent No.	Status	Title
United States	10/365,123 12-FEB-2003	US 7,381,801	Registered	Coverage of Products and Methods of Patents and Applications Currently In-Licensed from Ludwig Institute for Cancer Research (“Ludwig”) or Ludwig, Monash University; The Council of the Queensland Institute for Medical Research
United States	PCTUS0304185			Coverage of Products and Methods of Patents and Applications Currently In-Licensed from Ludwig Institute for Cancer Research (“Ludwig”) or Ludwig, Monash University; The Council of the Queensland Institute for Medical Research

Country	Application No./ Filing Date	Patent No.	Status	Title
United States	12/012,028 Divisional of 10/365,123 12-FEB-2003	US 7,897,743	Registered	Coverage of Products and Methods of Patents and Applications Currently In-Licensed from Ludwig Institute for Cancer Research (“Ludwig”) or Ludwig, Monash University; The Council of the Queensland Institute for Medical Research
Australia	2004210463 09-FEB-2004	AU2004210463	Registered	Coverage of Products and Methods of Patents and Applications Currently In-Licensed from Ludwig Institute for Cancer Research (“Ludwig”) or Ludwig, Monash University; The Council of the Queensland Institute for Medical Research
Europe	04709166 09-FEB-2004	EP1605959 (validated & fees paid in DE, ES, FR, GB, IT)	Registered 5 patents: Germany, Spain France, Great Britain, Italy	Coverage of Products and Methods of Patents and Applications Currently In-Licensed from Ludwig Institute

Country	Application No./ Filing Date	Patent No.	Status	Title
				for Cancer Research ("Ludwig") or Ludwig, Monash University; The Council of the Queensland Institute for Medical Research

Country	Application No./ Filing Date	Patent No.	Status	Title
United States	15/733,836 30-NOV-2020 National Phase of PCT/US2019/034900 31-MAY-2019	N/A	Pending	GM-CSF Gene-Editing CAR-T Cell Platform Technologies
Australia	2019277660 18-DEC-2020 National Phase of PCT/US2019/034900 31-MAY-2019	N/A	Pending	GM-CSF Gene-Editing CAR-T Cell Platform Technologies
Canada	3,101,991 27-NOV-2020 National Phase of PCT/US2019/034900 31-MAY-2019	N/A	Pending	GM-CSF Gene-Editing CAR-T Cell Platform Technologies
China	201980046671.2 12-JAN-2021 National Phase of PCT/US2019/034900 31-MAY-2019	N/A	Pending	GM-CSF Gene-Editing CAR-T Cell Platform Technologies
Europe	19812602.1 16-DEC-2020 Regional Phase of PCT/US2019/034900 31-MAY-2019	3801563	Registered	GM-CSF Gene-Editing CAR-T Cell Platform Technologies
Hong Kong	62021037939.9 31-Aug- 2021	N/A	Pending	GM-CSF Gene-Editing CAR-T Cell Platform Technologies
India	202017051020 24-NOV-2020 National Phase of PCT/US2019/034900 31-MAY-2019	N/A	Pending	GM-CSF Gene-Editing CAR-T Cell Platform Technologies
Japan	2020-566666 27-NOV-2020 National Phase of PCT/US2019/034900 31-MAY-2019	N/A	Pending	GM-CSF Gene-Editing CAR-T Cell Platform Technologies

Country	Application No./ Filing Date	Patent No.	Status	Title
S. Korea	10-2020-7038042 30-DEC-2020 National Phase of PCT/US2019/034900 31-MAY-2019	N/A	Pending	GM-CSF Gene- Editing CAR-T Cell Platform Technologies
Mexico	MX/a/2020/013017 01-DEC-2020 National Phase of PCT/US2019/034900 31-MAY-2019	N/A	Pending	GM-CSF Gene- Editing CAR-T Cell Platform Technologies
New Zealand	771339 18-DEC-2020 National Phase of PCT/US2019/034900 31-MAY-2019	N/A	Pending	GM-CSF Gene- Editing CAR-T Cell Platform Technologies
Russia	2020142342 22-DEC-2020 National Phase of PCT/US2019/034900 31-MAY-2019	2787828	Registered	GM-CSF Gene- Editing CAR-T Cell Platform Technologies

Country	Application No./ Filing Date	Patent No.	Status	Title
United States	16/269,572 07-FEB-2019 Priority: EP18158169.5, 22-02-2018 EP 18189562.4, 17-08-2018 and 18194549.4, 14-09-2018	11,655,293	Registered	Ligands To Gm-Csf Or Gm-Csf-Receptor For Use In Treatment Of A Haematologic Malignancy In A Patient Having Undergone Allo-Hct
United States	18/320,162 18-MAY-2023	N/A	Pending	Ligands To Gm-Csf Or Gm-Csf-Receptor For Use In Treatment Of A Haematologic Malignancy In A Patient Having Undergone Allo-Hct
United States	16/971,276 19-AUG-2020 PCT/EP2019/054493 22-FEB-2019 Priority: 16/26957207, 07-Feb-.2019; EP18158169, 22.02.2018; EP 18189562.4, 17.08.2018 and 18194549.4, 14.09.2018	N/A	Pending	Ligands To Gm-Csf Or Gm-Csf-Receptor For Use In Treatment Of A Haematologic Malignancy In A Patient Having Undergone Allo-Hct
Australia	2019224550 25-AUG- 2020 National Phase of PCT/EP2019/054493 22-FEB-2019	N/A	Pending	Ligands To Gm-Csf Or Gm-Csf-Receptor For Use In Treatment Of A Haematologic Malignancy In A Patient Having Undergone Allo-Hct

Country	Application No./ Filing Date	Patent No.	Status	Title
Brazil	1120200172537 22-DEC-2020 National Phase of PCT/EP2019/054493 22-FEB-2019	N/A	Pending	Ligands To Gm-Csf Or Gm-Csf-Receptor For Use In Treatment Of A Haematologic Malignancy In A Patient Having Undergone Allo-Hct
Canada	3,091,536 18-AUG-2020 National Phase of PCT/EP2019/054493 22-FEB-2019	N/A	Pending	Ligands To Gm-Csf Or Gm-Csf-Receptor For Use In Treatment Of A Haematologic Malignancy In A Patient Having Undergone Allo-Hct
China	201980020251.7 18-SEP- 2020 National Phase of PCT/EP2019/054493 22-FEB-2019	N/A	Pending	Ligands To Gm-Csf Or Gm-Csf-Receptor For Use In Treatment Of A Haematologic Malignancy In A Patient Having Undergone Allo-Hct
N/A	19705548.6 4-AUG-2020 Regional Phase of PCT/EP2019/054493 22-FEB-2019	N/A	Pending	Ligands To Gm-Csf Or Gm-Csf-Receptor For Use In Treatment Of A Haematologic Malignancy In A Patient Having Undergone Allo-Hct
N/A	62021025976.3	N/A	Pending	Ligands To Gm-Csf Or Gm-Csf-Receptor For Use In Treatment Of A Haematologic Malignancy In A Patient Having

Country	Application No./ Filing Date	Patent No.	Status	Title
				Undergone Allo-Hct
India	202017036791 26-AUG-2020 National Phase of PCT/EP2019/054493 22-FEB-2019	N/A	Pending	Ligands To Gm-Csf Or Gm-Csf-Receptor For Use In Treatment Of A Haematologic Malignancy In A Patient Having Undergone Allo-Hct
Japan	2020-543999 19-AUG- 2020 National Phase of PCT/EP2019/054493 22-FEB-2019	7278296	Registered	Ligands To Gm-Csf Or Gm-Csf-Receptor For Use In Treatment Of A Haematologic Malignancy In A Patient Having Undergone Allo-Hct
S. Korea	10-2020-7025898 8-SEP-2020 National Phase of PCT/EP2019/054493 22-FEB-2019	N/A	Pending	Ligands To Gm-Csf Or Gm-Csf-Receptor For Use In Treatment Of A Haematologic Malignancy In A Patient Having Undergone Allo-Hct
Mexico	MX/a/2020/008792 21-AUG- 2020 National Phase of PCT/EP2019/054493 22-FEB-2019	399683	Registered	Ligands To Gm-Csf Or Gm-Csf-Receptor For Use In Treatment Of A Haematologic Malignancy In A Patient Having Undergone Allo-Hct
Mexico Divisional	MX/a/2023/001357 30-JAN-2023	N/A	Pending	Ligands To Gm-Csf Or Gm-Csf-Receptor For Use In Treatment Of A

Country	Application No./ Filing Date	Patent No.	Status	Title
				Haematologic Malignancy In A Patient Having Undergone Allo-Hct
New Zealand	767415 25-AUG-2020 National Phase of PCT/EP2019/054493 22-FEB-2019	N/A	Pending	Ligands To Gm-Csf Or Gm-Csf-Receptor For Use In Treatment Of A Haematologic Malignancy In A Patient Having Undergone Allo-Hct
Russia	2020129401 7-SEP- 2020 National Phase of PCT/EP2019/054493 22-FEB-2019	2772132	Registered	Ligands To Gm-Csf Or Gm-Csf-Receptor For Use In Treatment Of A Haematologic Malignancy In A Patient Having Undergone Allo-Hct

Fill in this information to identify the case:

Debtor name Humanigen, Inc.

United States Bankruptcy Court for the: DISTRICT OF DELAWARE

Case number (if known) 24-10003 (BLS)

Check if this is an amended filing

Official Form 206D

Schedule D: Creditors Who Have Claims Secured by Property

12/15

Be as complete and accurate as possible.

1. Do any creditors have claims secured by debtor's property?

- No. Check this box and submit page 1 of this form to the court with debtor's other schedules. Debtor has nothing else to report on this form.
- Yes. Fill in all of the information below.

Fill in this information to identify the case:

Debtor name Humanigen, Inc.

United States Bankruptcy Court for the: DISTRICT OF DELAWARE

Case number (if known) 24-10003 (BLS)

Check if this is an amended filing

Official Form 206E/F
Schedule E/F: Creditors Who Have Unsecured Claims

12/15

Be as complete and accurate as possible. Use Part 1 for creditors with PRIORITY unsecured claims and Part 2 for creditors with NONPRIORITY unsecured claims. List the other party to any executory contracts or unexpired leases that could result in a claim. Also list executory contracts on *Schedule A/B: Assets - Real and Personal Property* (Official Form 206A/B) and on *Schedule G: Executory Contracts and Unexpired Leases* (Official Form 206G). Number the entries in Parts 1 and 2 in the boxes on the left. If more space is needed for Part 1 or Part 2, fill out and attach the Additional Page of that Part included in this form.

Part 1: List All Creditors with PRIORITY Unsecured Claims

1. Do any creditors have priority unsecured claims? (See 11 U.S.C. § 507).

- No. Go to Part 2.
 Yes. Go to line 2.

Part 2: List All Creditors with NONPRIORITY Unsecured Claims

3. List in alphabetical order all of the creditors with nonpriority unsecured claims. If the debtor has more than 6 creditors with nonpriority unsecured claims, fill out and attach the Additional Page of Part 2.

		Amount of claim	
3.1	Nonpriority creditor's name and mailing address Ajinomoto Bio-Pharma Services 11040 Roselle Street San Diego, CA 92121 Date(s) debt was incurred <u>Various</u> Last 4 digits of account number _	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input checked="" type="checkbox"/> Disputed Basis for the claim: <u>Trade Payables</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	<u>\$6,000.00</u>
3.2	Nonpriority creditor's name and mailing address APCER Life Sciences Inc. 111 Town Square Place Suite 860 Jersey City, NJ 07310 Date(s) debt was incurred <u>Various</u> Last 4 digits of account number _	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade Payables</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	<u>\$2,500.00</u>
3.3	Nonpriority creditor's name and mailing address Barliant, Ronald Address on File Date(s) debt was incurred <u>Various</u> Last 4 digits of account number _	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>BOD Fees</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	<u>\$33,000.00</u>
3.4	Nonpriority creditor's name and mailing address Bay Area Executive Offices 533 Airport Blvd, Suite 400 Burlingame, CA 94010-2013 Date(s) debt was incurred <u>Various</u> Last 4 digits of account number _	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>January unpaid rent</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	<u>\$1,340.32</u>

Debtor Name	Case number (if known)	24-10003 (BLS)
Humanigen, Inc. Name 3.5 Nonpriority creditor's name and mailing address BioWa, Inc. 212 Carnegie Center, Suite 101 Princeton, NJ 08540 Date(s) debt was incurred <u>Various</u> Last 4 digits of account number __	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade Payables</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$100,000.00
3.6 Nonpriority creditor's name and mailing address Boehm, Rainer Address on file Date(s) debt was incurred <u>Various</u> Last 4 digits of account number __	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>BOD Fees</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$43,500.00
3.7 Nonpriority creditor's name and mailing address Bryan Garnier Securities, LLC 750 Lexington Avenue New York, NY 10022 Date(s) debt was incurred <u>Various</u> Last 4 digits of account number __	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade Payables</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$78,647.50
3.8 Nonpriority creditor's name and mailing address Buxton, Cheryl Address on file Date(s) debt was incurred <u>Various</u> Last 4 digits of account number __	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>BOD Fees</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$18,701.00
3.9 Nonpriority creditor's name and mailing address Cardinal Health PO Box 978709 Dallas, TX 75397-8709 Date(s) debt was incurred <u>Various</u> Last 4 digits of account number __	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade Payables</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$43,196.30
3.10 Nonpriority creditor's name and mailing address CATALENT CTS (EDINBURGH) LTD 1 INCHWOOD PARK BATHGATE EH48 2FY United Kingdom Date(s) debt was incurred <u>Various</u> Last 4 digits of account number __	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade Payables</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$42,788.69
3.11 Nonpriority creditor's name and mailing address Catalent Indiana, LLC P O Box 734097 Chicago, IL 60673-4097 Date(s) debt was incurred <u>Various</u> Last 4 digits of account number __	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade Payables</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$202,079.90

Debtor Name	Case number (if known)	24-10003 (BLS)
Humanigen, Inc. <small>Name</small>		
3.12 Nonpriority creditor's name and mailing address Catalent Pharma Solutions - GALA (Madiso 25109 Network Place Chicago, IL 60673-1251 Date(s) debt was incurred <u>Various</u> Last 4 digits of account number <u> </u>	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input checked="" type="checkbox"/> Disputed Basis for the claim: <u>Trade Payables</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$361,604.49
3.13 Nonpriority creditor's name and mailing address Catalent Pharma Solutions - San Diego CS 14 Schoolhouse Road Somerset, NJ 08873 Date(s) debt was incurred <u>Various</u> Last 4 digits of account number <u> </u>	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade Payables</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$2,550.00
3.14 Nonpriority creditor's name and mailing address Catalent Pharma Solutions, LLC 25111 Network Place Chicago, IL 60673-1251 Date(s) debt was incurred <u>Various</u> Last 4 digits of account number <u> </u>	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input checked="" type="checkbox"/> Disputed Basis for the claim: <u>Trade Payables</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$123,336.43
3.15 Nonpriority creditor's name and mailing address Charles River Laboratories - Ashland (IL GPO 27812 New York, NY 10087-7812 Date(s) debt was incurred <u>Various</u> Last 4 digits of account number <u> </u>	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade Payables</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$491,178.00
3.16 Nonpriority creditor's name and mailing address Charles Russell Speechlys LLP 5 Fleet Place London, EC4M 7RD United Kingdom Date(s) debt was incurred <u>Various</u> Last 4 digits of account number <u> </u>	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade Payables</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$2,080.41
3.17 Nonpriority creditor's name and mailing address Chime Biologics (Wuhan) Co.,Ltd NO. 388 GAOXIN ROAD (NO.2) EAST LAKE HI-TECH DEVELOPMENT ZONE HUBEI PROVINCE WUHAN 430000 CHINA Date(s) debt was incurred <u>Various</u> Last 4 digits of account number <u> </u>	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade Payables</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$4,588,481.00
3.18 Nonpriority creditor's name and mailing address CIT Technology Financing Inc. PO Box 100706 Pasadena, CA 91189 Date(s) debt was incurred <u>Various</u> Last 4 digits of account number <u> </u>	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade Payables</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$3,458.20

Debtor Name	Case number (if known)	24-10003 (BLS)
Humanigen, Inc. Name		
3.19 Nonpriority creditor's name and mailing address Clinigen Healthcare Limited Pitcairn House Crown Square Centrum 100 Burton-on-Trent Staffordshire DE14 2WW United Kingdom Date(s) debt was incurred <u>Various</u> Last 4 digits of account number _	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input checked="" type="checkbox"/> Disputed Basis for the claim: <u>Trade Payables</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$23,973.97
3.20 Nonpriority creditor's name and mailing address Complete Discovery Source Chriesbaumstrasse 6 CH-8604 Volketswil Switzerland Date(s) debt was incurred <u>Various</u> Last 4 digits of account number _	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade Payables</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$41,940.90
3.21 Nonpriority creditor's name and mailing address Computershare, Inc. Dept CH 19228 Palatine, IL 60055-9228 Date(s) debt was incurred <u>Various</u> Last 4 digits of account number _	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade Payables</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$9,694.13
3.22 Nonpriority creditor's name and mailing address Copyright Clearance Cent 29118 Network Place IL 61673-1291 Date(s) debt was incurred <u>Various</u> Last 4 digits of account number _	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input checked="" type="checkbox"/> Disputed Basis for the claim: <u>Trade Payables</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$2,569.05
3.23 Nonpriority creditor's name and mailing address CPA Global 2318 Mill Road, 12th Floor Alexandria, VA 22314 Date(s) debt was incurred <u>Various</u> Last 4 digits of account number _	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade Payables</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$24,783.68
3.24 Nonpriority creditor's name and mailing address CRF Inc PO Box 536379 Pittsburgh, PA 15253-5905 Date(s) debt was incurred <u>Various</u> Last 4 digits of account number _	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade Payables</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$2,728.15
3.25 Nonpriority creditor's name and mailing address CTI Clinical Trial Services, Inc 100 E. RiverCenter Blvd. Suite 1600 Covington, KY 41011 Date(s) debt was incurred <u>Various</u> Last 4 digits of account number _	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input checked="" type="checkbox"/> Disputed Basis for the claim: <u>Trade Payables</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$594,073.00

Debtor Name	Case number (if known)	24-10003 (BLS)
Humanigen, Inc. Name		
3.26 Nonpriority creditor's name and mailing address Dawson James Securities, Inc. 1 North Federal Highway, Ste 500 Boca Raton, FL 33432 Date(s) debt was incurred <u>Various</u> Last 4 digits of account number _	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade Payables</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$5,368.70
3.27 Nonpriority creditor's name and mailing address E*Trade Financial Corp Services Attn: Accounts Receivable PO Box 3512 Arlington, VA 22203 Date(s) debt was incurred <u>Various</u> Last 4 digits of account number _	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade Payables</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$62,500.00
3.28 Nonpriority creditor's name and mailing address FASB PO Box 418272 Boston, MA 02241-8272 Date(s) debt was incurred <u>Various</u> Last 4 digits of account number _	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade Payables</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$744.60
3.29 Nonpriority creditor's name and mailing address Fisher BioServices, Inc. PO Box 418395 Boston, MA 02241-8395 Date(s) debt was incurred <u>Various</u> Last 4 digits of account number _	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade Payables</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$2,827.54
3.30 Nonpriority creditor's name and mailing address Hogan Lovells US LLP 875 Third Avenue New York, NY 10022 Date(s) debt was incurred <u>Various</u> Last 4 digits of account number _	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input checked="" type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade Payables</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$1,110,634.33
3.31 Nonpriority creditor's name and mailing address ICON Clinical Research Ltd South County Business Park Leopardstown D18 X5R3, Ireland Date(s) debt was incurred <u>Various</u> Last 4 digits of account number _	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade Payables</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$296.88
3.32 Nonpriority creditor's name and mailing address Incorporating Services, Ltd. 3500 S DuPont Hwy Dover, DE 19901 Date(s) debt was incurred <u>Various</u> Last 4 digits of account number _	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade Payables</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$2,600.00

Debtor Name	Case number (if known)	24-10003 (BLS)
Humanigen, Inc. Name		
3.33 Nonpriority creditor's name and mailing address Intertrust Management Ireland Limited 2nd floor, 1-2 Victoria Buildings Haddington Road Dublin, D04 XN32 IRELAND Date(s) debt was incurred <u>Various</u> Last 4 digits of account number __	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade Payables</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$7,120.56
3.34 Nonpriority creditor's name and mailing address John Arthur Hohneker Address on file Date(s) debt was incurred <u>Various</u> Last 4 digits of account number __	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>BOD Fees</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$14,946.00
3.35 Nonpriority creditor's name and mailing address KBA Docusys 32900 Alvarado Niles Rd # 100 Union City, CA 94587 Date(s) debt was incurred <u>Various</u> Last 4 digits of account number __	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade Payables</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$698.69
3.36 Nonpriority creditor's name and mailing address Kleinberg Kaplan Wolff & Cohen P.C. 500 Fifth Avenue New York, NY 10110 Date(s) debt was incurred <u>Various</u> Last 4 digits of account number __	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade Payables</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$51,172.49
3.37 Nonpriority creditor's name and mailing address KP Pharmaceutical Technology, Inc. 1212 West Rappel Avenue Bloomington, IN 47404-1702 Date(s) debt was incurred <u>Various</u> Last 4 digits of account number __	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade Payables</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$4,800.00
3.38 Nonpriority creditor's name and mailing address Lonza Sales Ltd Munchensteinerstrasse 38 Basel CH-4002, Switzerland Date(s) debt was incurred <u>Various</u> Last 4 digits of account number __	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade Payables</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$752,580.55
3.39 Nonpriority creditor's name and mailing address LSCS Holdings, Inc 190 N Milwaukee St. Milwaukee, WI 53202 Date(s) debt was incurred <u>Various</u> Last 4 digits of account number __	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input checked="" type="checkbox"/> Disputed Basis for the claim: <u>Trade Payables</u> Is the claim subject to offset? <input type="checkbox"/> No <input checked="" type="checkbox"/> Yes	\$4,769,205.00

Debtor	Name	Case number (if known)	24-10003 (BLS)
3.40	Humanigen, Inc. Ludwig Institute For Cancer Research Ltd PO Box 8070 ZURICH SWITZERLAND Date(s) debt was incurred <u>Various</u> Last 4 digits of account number <u> </u>	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade Payables</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$30,000.00
3.41	Marken LLP 215 W. Bridgewater Road Aston, PA 19014 Date(s) debt was incurred <u>Various</u> Last 4 digits of account number <u> </u>	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade Payables</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$603,643.54
3.42	Morvillo Abramowitz Grand Iason & Anello 565 Fifth Avenue New York, NY 10017 Date(s) debt was incurred <u>Various</u> Last 4 digits of account number <u> </u>	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade Payables</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$69,681.00
3.43	NASDAQ Corp Solutions, LLC PO Box 780700 Philadelphia, PA 19178-0700 Date(s) debt was incurred <u>Various</u> Last 4 digits of account number <u> </u>	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade Payables</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$3,865.00
3.44	NTherapeutics LLC 10705 E. Butherus Drive Scottsdale, AZ 85255-8588 Date(s) debt was incurred <u>Various</u> Last 4 digits of account number <u> </u>	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade Payables</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$15,000.00
3.45	Patheon Biologics LLC 4766 LaGuardia Drive Saint Louis, MO 63134 Date(s) debt was incurred <u> </u> Last 4 digits of account number <u> </u>	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input checked="" type="checkbox"/> Disputed Basis for the claim: <u> </u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$24,899,110.56
3.46	PCAOB PO Box 418631 Boston, MA 02241-8631 Date(s) debt was incurred <u>Various</u> Last 4 digits of account number <u> </u>	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade Payables</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$4,579.80

Debtor Name	Case number (if known)	24-10003 (BLS)
Humanigen, Inc. <small>Name</small>		
3.47 Nonpriority creditor's name and mailing address Pearl Cohen Zedek Latzer Baratz LLP 1500 Broadway, 12th Fl. New York, NY 10036 Date(s) debt was incurred <u>Various</u> Last 4 digits of account number _	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade Payables</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$229,149.00
3.48 Nonpriority creditor's name and mailing address Pharmaceutical Research Assoc., Inc. (PR PO Box 200072 Dallas, TX 75320-0072 Date(s) debt was incurred <u>Various</u> Last 4 digits of account number _	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade Payables</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$68,221.17
3.49 Nonpriority creditor's name and mailing address Polsinelli PC PO Box 878681 Kansas City, MO 64187-8681 Date(s) debt was incurred <u>Various</u> Last 4 digits of account number _	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade Payables</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$792,182.70
3.50 Nonpriority creditor's name and mailing address Q4 Inc. 469-A King St. W TORONTO, ON M5V 1K4, CANADA Date(s) debt was incurred <u>Various</u> Last 4 digits of account number _	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade Payables</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$28,358.87
3.51 Nonpriority creditor's name and mailing address RoseRyan 35473 Dumbarton Court Newark, CA 94560 Date(s) debt was incurred <u>Various</u> Last 4 digits of account number _	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade Payables</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$420.00
3.52 Nonpriority creditor's name and mailing address RX Medical Dynamics, LLC 156 Fifth Avenue Suite 1119 New York, IA 50000 Date(s) debt was incurred <u>Various</u> Last 4 digits of account number _	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade Payables</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$50,000.00
3.53 Nonpriority creditor's name and mailing address Say Technologies 245 8th Ave # 1040 New York, NY 10011 Date(s) debt was incurred <u>Various</u> Last 4 digits of account number _	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade Payables</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$20,000.00

Debtor Name	Case number (if known)	24-10003 (BLS)
Humanigen, Inc. <small>Name</small>		
3.54 Nonpriority creditor's name and mailing address Shook, Hardy & Bacon L.L.P 2555 Grand Blvd Kansas City, MO 64108 Date(s) debt was incurred <u>Various</u> Last 4 digits of account number <u> </u>	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade Payables</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$67,479.53
3.55 Nonpriority creditor's name and mailing address Silva IT Pros, Inc. PO BOX 2204 Brisbane, CA 94005 Date(s) debt was incurred <u>Various</u> Last 4 digits of account number <u> </u>	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade Payables</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$1,395.00
3.56 Nonpriority creditor's name and mailing address The Wall Street Transcript 622 3rd Avenue 34th Floor New York, NY 10017 Date(s) debt was incurred <u>Various</u> Last 4 digits of account number <u> </u>	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input checked="" type="checkbox"/> Disputed Basis for the claim: <u>Trade Payables</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$700.00
3.57 Nonpriority creditor's name and mailing address Universitat Zurich Hirschengraben 48 ZURICH 8001 SWITZERLAND Date(s) debt was incurred <u>Various</u> Last 4 digits of account number <u> </u>	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade Payables</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$350,000.00
3.58 Nonpriority creditor's name and mailing address Vince & Associates 10103 Metcalf Avenue Overland Park, KS 66212 Date(s) debt was incurred <u>Various</u> Last 4 digits of account number <u> </u>	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade Payables</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$91,700.71
3.59 Nonpriority creditor's name and mailing address Vital Records Holding, LLC Dept. 5874 PO Box 11407 Birmingham, AL 35246-5874 Date(s) debt was incurred <u>Various</u> Last 4 digits of account number <u> </u>	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade Payables</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$1,010.79
3.60 Nonpriority creditor's name and mailing address Yili Kevin Xie Address on file Date(s) debt was incurred <u>Various</u> Last 4 digits of account number <u> </u>	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>BOD Fees</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$19,908.00

Part 3: List Others to Be Notified About Unsecured Claims

Debtor Humanigen, Inc.
Name

Case number (if known) 24-10003 (BLS)

4. List in alphabetical order any others who must be notified for claims listed in Parts 1 and 2. Examples of entities that may be listed are collection agencies, assignees of claims listed above, and attorneys for unsecured creditors.

If no others need to be notified for the debts listed in Parts 1 and 2, do not fill out or submit this page. If additional pages are needed, copy the next page.

Name and mailing address

On which line in Part 1 or Part 2 is the related creditor (if any) listed?

Last 4 digits of account number, if any

Part 4: Total Amounts of the Priority and Nonpriority Unsecured Claims

5. Add the amounts of priority and nonpriority unsecured claims.

5a. Total claims from Part 1

5b. Total claims from Part 2

5c. Total of Parts 1 and 2
 Lines 5a + 5b = 5c.

		Total of claim amounts
5a.	\$	0.00
5b.	+	40,976,106.13
5c.	\$	40,976,106.13

Fill in this information to identify the case:

Debtor name Humanigen, Inc.

United States Bankruptcy Court for the: DISTRICT OF DELAWARE

Case number (if known) 24-10003 (BLS)

Check if this is an amended filing

Official Form 206G

Schedule G: Executory Contracts and Unexpired Leases

12/15

Be as complete and accurate as possible. If more space is needed, copy and attach the additional page, number the entries consecutively.

1. Does the debtor have any executory contracts or unexpired leases?

No. Check this box and file this form with the debtor's other schedules. There is nothing else to report on this form.

Yes. Fill in all of the information below even if the contacts of leases are listed on *Schedule A/B: Assets - Real and Personal Property* (Official Form 206A/B).

2. List all contracts and unexpired leases

State the name and mailing address for all other parties with whom the debtor has an executory contract or unexpired lease

2.1.	State what the contract or lease is for and the nature of the debtor's interest State the term remaining List the contract number of any government contract	Technology Transfer, Validation and Commercial Fill/Finish Services Agreement, dated as of December 10, 2020 Undetermined	Ajinomoto Althea, Inc. dba Ajinomoto 11040 Roselle Street San Diego, CA 92121
2.2.	State what the contract or lease is for and the nature of the debtor's interest State the term remaining List the contract number of any government contract	Material Transfer Agreement, dated August 31, 2021 Undetermined	Ajinomoto Co. Inc. 11040 Roselle Street San Diego, CA 92121
2.3.	State what the contract or lease is for and the nature of the debtor's interest State the term remaining List the contract number of any government contract	Statement of Work, dated August 30, 2021	Ajinomoto Co. Inc. 11040 Roselle Street San Diego, CA 92121

Debtor 1 **Humanigen, Inc.**
 First Name Middle Name Last Name

Case number (if known) 24-10003 (BLS)

Additional Page if You Have More Contracts or Leases

2. List all contracts and unexpired leases State the name and mailing address for all other parties with whom the debtor has an executory contract or unexpired lease

2.4. State what the contract or lease is for and the nature of the debtor's interest **Master Services Agreement dated March 10, 2022**

State the term remaining **Five years from March 10, 2022, automatic 12 month renewals**

List the contract number of any government contract _____

**APCER Life Sciences, Inc.
 3 INDEPENDENCE WAY, SUITE 300
 Princeton, NJ 08540**

2.5. State what the contract or lease is for and the nature of the debtor's interest **Statement of Work I effective March 28, 2022**

State the term remaining **Five years from March 10, 2022, automatic 12 month renewals**

List the contract number of any government contract _____

**APCER Life Sciences, Inc.
 3 INDEPENDENCE WAY, SUITE 300
 Princeton, NJ 08540**

2.6. State what the contract or lease is for and the nature of the debtor's interest **Non-Exclusive License Agreement, dated October 14, 2010**

State the term remaining **90 days notice**

List the contract number of any government contract _____

**BioWa, Inc.
 212 Carnegie Center, Suite 101
 Princeton, NJ 08540**

2.7. State what the contract or lease is for and the nature of the debtor's interest **Master Supply Agreement**

State the term remaining **No stated date**

List the contract number of any government contract _____

**Bryllan LLC
 12501 Grand River Ave.
 Brighton, MI 48116**

2.8. State what the contract or lease is for and the nature of the debtor's interest **Traditional 3PL Operating Guidelines, dated as of September 9, 2020**

State the term remaining **3 years from first shipment of FDA approved product, automatic 1 year renewals**

List the contract number of any government contract _____

**Cardinal Health 105, Inc.
 7000 Cardinal Place
 Dublin, OH 43017**

Debtor 1 **Humanigen, Inc.**
 First Name Middle Name Last Name

Case number (if known) 24-10003 (BLS)

Additional Page if You Have More Contracts or Leases

2. List all contracts and unexpired leases

State the name and mailing address for all other parties with whom the debtor has an executory contract or unexpired lease

2.9. State what the contract or lease is for and the nature of the debtor's interest **Amended and Restated Quality Agreement**

State the term remaining **3 years from first shipment of FDA approved product, automatic 1 year renewals**

List the contract number of any government contract _____ **Cardinal Health 105, LLC
501 Mason Road, Suite 200
La Vergne, TN 37086**

2.10. State what the contract or lease is for and the nature of the debtor's interest **Exclusive Distribution Agreement, dated September 9, 2020**

State the term remaining **3 years from first shipment of FDA approved product, automatic 1 year renewals**

List the contract number of any government contract _____ **Cardinal Health 105, LLC
501 Mason Road, Suite 200
La Vergne, TN 37086**

2.11. State what the contract or lease is for and the nature of the debtor's interest **Development and Manufacturing Agreement, dated as of June 16, 2005**

State the term remaining **3 years from first shipment of FDA approved product, automatic 1 year renewals**

List the contract number of any government contract _____ **Cardinal Health PTS, LLC, Gala Biotechno
8137 Forsythia Street
Middleton, WI 53562**

2.12. State what the contract or lease is for and the nature of the debtor's interest **Project Plan #12, dated April 13, 2021**

State the term remaining **60 months from July 31, 2020**

List the contract number of any government contract _____ **Catalent Indiana, LLC,
1300 South Patterson Drive
Bloomington, IN 47403**

Debtor 1 **Humanigen, Inc.**
First Name Middle Name Last Name

Case number (if known) 24-10003 (BLS)

Additional Page if You Have More Contracts or Leases

2. List all contracts and unexpired leases State the name and mailing address for all other parties with whom the debtor has an executory contract or unexpired lease

2.13. State what the contract or lease is for and the nature of the debtor's interest **Change Order and Project Plan, dated December 12, 2022**

State the term remaining **60 months from July 31, 2020**

List the contract number of any government contract _____

**Catalent Pharma Solutions, LLC
 1300 South Patterson Drive
 Bloomington, IN 47403**

2.14. State what the contract or lease is for and the nature of the debtor's interest **Change Order and Project Plan, dated February 20, 2023**

State the term remaining **60 months from July 31, 2020**

List the contract number of any government contract _____

**Catalent Pharma Solutions, LLC
 1300 South Patterson Drive
 Bloomington, IN 47403**

2.15. State what the contract or lease is for and the nature of the debtor's interest **Change Order and Project Plan, dated February 8, 2023**

State the term remaining **60 months from July 31, 2020**

List the contract number of any government contract _____

**Catalent Pharma Solutions, LLC
 1300 South Patterson Drive
 Bloomington, IN 47403**

2.16. State what the contract or lease is for and the nature of the debtor's interest **GPEX-Derived Cell Line Sale Agreement, dated as of March 1, 2013**

State the term remaining **60 months from July 31, 2020**

List the contract number of any government contract _____

**Catalent Pharma Solutions, LLC
 1300 South Patterson Drive
 Bloomington, IN 47403**

2.17. State what the contract or lease is for and the nature of the debtor's interest **Multiple Facility Clinical Supply and Services Agreement, Drug Substance and Drug Product, dated July 31, 2020**

State the term remaining **60 months from July 31, 2020**

List the contract number of any government contract _____

**Catalent Pharma Solutions, LLC
 1300 South Patterson Drive
 Bloomington, IN 47403**

Debtor 1 **Humanigen, Inc.**
 First Name Middle Name Last Name

Case number (if known) 24-10003 (BLS)

Additional Page if You Have More Contracts or Leases

2. List all contracts and unexpired leases

State the name and mailing address for all other parties with whom the debtor has an executory contract or unexpired lease

2.18. State what the contract or lease is for and the nature of the debtor's interest **Project Plan and Quote for Stability Testing, dated September 3, 2013**
 State the term remaining **60 months from July 31, 2020**
 List the contract number of any government contract _____ **Catalent Pharma Solutions, LLC
 1300 South Patterson Drive
 Bloomington, IN 47403**

2.19. State what the contract or lease is for and the nature of the debtor's interest **Project Plan, dated April 27, 2022**
 State the term remaining **60 months from July 31, 2020**
 List the contract number of any government contract _____ **Catalent Pharma Solutions, LLC
 1300 South Patterson Drive
 Bloomington, IN 47403**

2.20. State what the contract or lease is for and the nature of the debtor's interest **Project Plan, dated April 28, 2022**
 State the term remaining **60 months from July 31, 2020**
 List the contract number of any government contract _____ **Catalent Pharma Solutions, LLC
 1300 South Patterson Drive
 Bloomington, IN 47403**

2.21. State what the contract or lease is for and the nature of the debtor's interest **Project Plan, dated April 30, 2018**
 State the term remaining **60 months from July 31, 2020**
 List the contract number of any government contract _____ **Catalent Pharma Solutions, LLC
 1300 South Patterson Drive
 Bloomington, IN 47403**

2.22. State what the contract or lease is for and the nature of the debtor's interest **Project Plan, dated May 2, 2022**
 State the term remaining **60 months from July 31, 2020**
 List the contract number of any government contract _____ **Catalent Pharma Solutions, LLC
 1300 South Patterson Drive
 Bloomington, IN 47403**

Debtor 1 **Humanigen, Inc.**
 First Name Middle Name Last Name

Case number (if known) 24-10003 (BLS)

Additional Page if You Have More Contracts or Leases

2. List all contracts and unexpired leases State the name and mailing address for all other parties with whom the debtor has an executory contract or unexpired lease

2.23. State what the contract or lease is for and the nature of the debtor's interest **Statement of Work, dated February 23, 2021**

State the term remaining **60 months from July 31, 2020**

List the contract number of any government contract _____

**Catalent Pharma Solutions, LLC
 1300 South Patterson Drive
 Bloomington, IN 47403**

2.24. State what the contract or lease is for and the nature of the debtor's interest **Change Order and Project Plan, dated February 28, 2022**

State the term remaining **60 months from July 31, 2020**

List the contract number of any government contract _____

**Catalent Pharma Solutions, LLC
 1300 South Patterson Drive
 Bloomington, IN 47403**

2.25. State what the contract or lease is for and the nature of the debtor's interest **Master Services Agreement, dated as of May 15, 2021**

State the term remaining **May 2026 or until all work orders are completed unless terminated earlier**

List the contract number of any government contract _____

**Chime Biologics (Wuhan) Co.,Ltd
 NO. 388 GAOXIN ROAD (NO.2)
 EAST LAKE HI-TECH DEVELOPMENT ZONE
 HUBEI PROVINCE
 WUHAN 430000 CHINA**

2.26. State what the contract or lease is for and the nature of the debtor's interest **Product Distribution Agreement**

State the term remaining **90 days notice or immediately upon insolvency**

List the contract number of any government contract _____

**Clinigen Healthcare Limited
 Pitcairn House Crown Square
 Centrum 100
 Burton-on-Trent Staffordshire
 DE14 2WW United Kingdom**

2.27. State what the contract or lease is for and the nature of the debtor's interest **Master Services Agreement, dated April 8, 2020**

State the term remaining **Until terminated**

List the contract number of any government contract _____

**CTI-Clinical Trial Services Inc.
 100 E. RiverCenter Blvd. Suite 1600
 Covington, KY 41011**

Debtor 1 **Humanigen, Inc.**
 First Name Middle Name Last Name

Case number (if known) 24-10003 (BLS)

Additional Page if You Have More Contracts or Leases

2. List all contracts and unexpired leases State the name and mailing address for all other parties with whom the debtor has an executory contract or unexpired lease

2.28. State what the contract or lease is for and the nature of the debtor's interest **Material Transfer Agreement, dated May 25, 2023**

State the term remaining **Emory University**

List the contract number of any government contract **Office of Technology Transfer**
1599 Clifton Road Northeast, 4th Floor
Atlanta, GA 30322

2.29. State what the contract or lease is for and the nature of the debtor's interest **Master Project Agreement, dated February 29, 2008, as amended by Amendment No. 1, dated October 7, 2021**

State the term remaining **30 days notice**

List the contract number of any government contract **Fisher BioServices Inc.**
14665 Rothgeb Drive
Rockville, MD 20850

2.30. State what the contract or lease is for and the nature of the debtor's interest **Funding Agreement - Ifabotuzumab, dated June 2, 2022**

State the term remaining **termination at any time**

List the contract number of any government contract **Humanigen Australia Pty Ltd**
181 Williams Street
Melbourne VIC 3000
Australia

2.31. State what the contract or lease is for and the nature of the debtor's interest **Funding Agreement - Lenzilumab, dated June 2, 2022**

State the term remaining **termination at any time**

List the contract number of any government contract **Humanigen Australia Pty Ltd**
181 Williams Street
Melbourne VIC 3000
Australia

2.32. State what the contract or lease is for and the nature of the debtor's interest **Intellectual Property License - Ifabotuzumab, dated June 2, 2022**

State the term remaining **termination at any time**

List the contract number of any government contract **Humanigen Australia Pty Ltd**
181 Williams Street
Melbourne VIC 3000
Australia

Debtor 1 **Humanigen, Inc.**
First Name Middle Name Last Name

Case number (if known) 24-10003 (BLS)

Additional Page if You Have More Contracts or Leases

2. List all contracts and unexpired leases State the name and mailing address for all other parties with whom the debtor has an executory contract or unexpired lease

2.33. State what the contract or lease is for and the nature of the debtor's interest **Intellectual Property License - Lenzilumab, dated August 25, 2020**

State the term remaining **termination at any time**

List the contract number of any government contract _____

**Humanigen Australia Pty Ltd
 181 Williams Street
 Melbourne VIC 3000
 Australia**

2.34. State what the contract or lease is for and the nature of the debtor's interest **Bioanalytical Work Order, dated as of July 13, 2021**

State the term remaining **60 days notice**

List the contract number of any government contract _____

**ICON Clinical Research Limited
 8282 Halsey Road
 Whitesboro, NY 13492**

2.35. State what the contract or lease is for and the nature of the debtor's interest **Cell Bank Storage Agreement, dated as of May 4, 2020**

State the term remaining **30 days**

List the contract number of any government contract _____

**Lonza Sales AG
 Munchensteinerstrasse 38
 Basel
 CH-4002, Switzerland**

2.36. State what the contract or lease is for and the nature of the debtor's interest **Development and Manufacturing Services Agreement, dated October 16, 2025**

State the term remaining **10/16/2025**

List the contract number of any government contract _____

**Lonza Sales Ltd
 Munchensteinerstrasse 38
 Basel
 CH-4002, Switzerland**

2.37. State what the contract or lease is for and the nature of the debtor's interest **Development and License Agreement, dated May 11, 2004**

State the term remaining **30 days notice**

List the contract number of any government contract _____

**Ludwig Institute for Cancer Research
 Stadelhoferstrasse 22
 801 Zurich Switzerland**

Debtor 1 **Humanigen, Inc.**
 First Name Middle Name Last Name

Case number (if known) 24-10003 (BLS)

Additional Page if You Have More Contracts or Leases

2. List all contracts and unexpired leases

State the name and mailing address for all other parties with whom the debtor has an executory contract or unexpired lease

2.38. State what the contract or lease is for and the nature of the debtor's interest **Master Service Agreement, dated January 18, 2021**

State the term remaining **1/18/2024**

List the contract number of any government contract _____

**Marken LLP
 215 W. Bridgewater Road
 Bridgewater Business Park Aston
 Aston, PA 19014**

2.39. State what the contract or lease is for and the nature of the debtor's interest **Preclinical Research Agreement dated July 1, 2020 (HUM-257821) FP00107312**

State the term remaining _____

List the contract number of any government contract _____

**Mayo Clinic
 PO BOX 860334
 Minneapolis, MN 55486**

2.40. State what the contract or lease is for and the nature of the debtor's interest **Preclinical Research Agreement dated July 1, 2020 (HUM-257820) FP00107203**

State the term remaining **30 days notice**

List the contract number of any government contract _____

**Mayo Clinic
 PO BOX 860334
 Minneapolis, MN 55486**

2.41. State what the contract or lease is for and the nature of the debtor's interest **Development Services Agreement**

State the term remaining **Until services completed**

List the contract number of any government contract _____

**Patheon Biologics LLC
 4766 LaGuardia Drive
 Saint Louis, MO 63134**

2.42. State what the contract or lease is for and the nature of the debtor's interest **Media Outreach Services**

State the term remaining **1/31/2026**

List the contract number of any government contract _____

**Rx Medical Dynamics, LLC
 156 Fifth Avenue Suite 1119
 New York, NY 10010**

Debtor 1 **Humanigen, Inc.**
First Name Middle Name Last Name

Case number (if known) 24-10003 (BLS)

Additional Page if You Have More Contracts or Leases

2. List all contracts and unexpired leases State the name and mailing address for all other parties with whom the debtor has an executory contract or unexpired lease

2.43. State what the contract or lease is for and the nature of the debtor's interest **Sage Master Services Agreement, dated May 22, 2020**

State the term remaining **10 days notice**

List the contract number of any government contract _____

**SAGE Engineering Services Ltd.
 1452 Wallace Road
 Oakville, ON L6L 2Y2
 Canada**

2.44. State what the contract or lease is for and the nature of the debtor's interest **Shareholder Communication Services**

State the term remaining **Until the expiration or termination of all Schedules**

List the contract number of any government contract _____

**Say Technologies
 245 8th Ave # 1040
 New York, NY 10011**

2.45. State what the contract or lease is for and the nature of the debtor's interest **Precision Medicine for Chronic Myelomonocytic Leukemia: A Phase II Trial Studying the Efficacy of Lenzilumab and High Dose Ascorbate with Azacitidine Based on Molecular Profiling**

State the term remaining _____

List the contract number of any government contract _____

**South Australian H. & Med. Res. Ins. Ltd
 North Terrace
 Adelaide SA 5000
 Australia**

2.46. State what the contract or lease is for and the nature of the debtor's interest **Investigator Initiated Research Agreement Interventional Study, dated as of May 3, 2017 open ended, until duration of the study**

State the term remaining _____

List the contract number of any government contract _____

**The Olivia Newton-John Cancer Res. Inst.
 Level 5, Austin Health
 145 Studley Road
 Heidelberg, Victoria 94080
 Australia**

Debtor 1 **Humanigen, Inc.**

First Name

Middle Name

Last Name

Case number (if known)

24-10003 (BLS)

Additional Page if You Have More Contracts or Leases**2. List all contracts and unexpired leases**

State the name and mailing address for all other parties with whom the debtor has an executory contract or unexpired lease

2.47. State what the contract or lease is for and the nature of the debtor's interest

State the term remaining

List the contract number of any government contract

**Pre-clinical
Collaboration
Agreement - Industry,
dated as of December
22, 2021
open ended, until
duration of the study****The Olivia Newton-John Cancer Res. Inst.
Level 5, Austin Health
145 Studley Road
Heidelberg, Victoria 94080
Australia**

2.48. State what the contract or lease is for and the nature of the debtor's interest

State the term remaining

List the contract number of any government contract

**Variation Agreement,
dated as of September
20, 2022****open ended, until
duration of the study****The Olivia Newton-John Cancer Res. Inst.
Level 5, Austin Health
145 Studley Road
Heidelberg, Victoria 94080
Australia**

2.49. State what the contract or lease is for and the nature of the debtor's interest

State the term remaining

List the contract number of any government contract

**Collaborative
Investigator Initiated
Clinical Trial
Agreement, dated
October 28, 2021,
which is related to the
Project RAtIng: Risk
Adapted Therapy in
Acute GvHD, and the
first variation thereto,
dated December 14,
2021, and the second
variation thereto, dated
November 11, 2022
30 days****The University of Birmingham
Cancer Research UK Clinical Trials Unit
Institute of Cancer and Genomic Sciences
Edgbaston, Birmingham, B15 2TT
United Kingdom**

2.50. State what the contract or lease is for and the nature of the debtor's interest

State the term remaining

List the contract number of any government contract

**License Agreement,
dated July 19, 2019****3 months provided that
company pays the
\$350K license fee
within 6 months of Nov
1, 2023.****University of Zurich
Ramistrasse 71
CH-8006 Zurich Switzerland**

Debtor 1 **Humanigen, Inc.**
First Name Middle Name Last Name

Case number (if known) 24-10003 (BLS)

Additional Page if You Have More Contracts or Leases

2. List all contracts and unexpired leases

State the name and mailing address for all other parties with whom the debtor has an executory contract or unexpired lease

2.51. State what the contract or lease is for and the nature of the debtor's interest **CMC Advisory Services**

State the term remaining **Until terminated**

List the contract number of any government contract _____

**Verta Life Sciences LLC
4242 Six Forks Rd Suite 1550
Raleigh, NC 27609**

Fill in this information to identify the case:

Debtor name Humanigen, Inc.

United States Bankruptcy Court for the: DISTRICT OF DELAWARE

Case number (if known) 24-10003 (BLS)

Check if this is an amended filing

Official Form 202

Declaration Under Penalty of Perjury for Non-Individual Debtors

12/15

An individual who is authorized to act on behalf of a non-individual debtor, such as a corporation or partnership, must sign and submit this form for the schedules of assets and liabilities, any other document that requires a declaration that is not included in the document, and any amendments of those documents. This form must state the individual's position or relationship to the debtor, the identity of the document, and the date. Bankruptcy Rules 1008 and 9011.

WARNING -- Bankruptcy fraud is a serious crime. Making a false statement, concealing property, or obtaining money or property by fraud in connection with a bankruptcy case can result in fines up to \$500,000 or imprisonment for up to 20 years, or both. 18 U.S.C. §§ 152, 1341, 1519, and 3571.

Declaration and signature

I am the president, another officer, or an authorized agent of the corporation; a member or an authorized agent of the partnership; or another individual serving as a representative of the debtor in this case.

I have examined the information in the documents checked below and I have a reasonable belief that the information is true and correct:

- Schedule A/B: Assets—Real and Personal Property* (Official Form 206A/B)
- Schedule D: Creditors Who Have Claims Secured by Property* (Official Form 206D)
- Schedule E/F: Creditors Who Have Unsecured Claims* (Official Form 206E/F)
- Schedule G: Executory Contracts and Unexpired Leases* (Official Form 206G)
- Schedule H: Codebtors* (Official Form 206H)
- Summary of Assets and Liabilities for Non-Individuals* (Official Form 206Sum)
- Amended Schedule _____
- Chapter 11 or Chapter 9 Cases: List of Creditors Who Have the 20 Largest Unsecured Claims and Are Not Insiders (Official Form 204)
- Other document that requires a declaration _____

I declare under penalty of perjury that the foregoing is true and correct.

Executed on February 9, 2024

X /s/ Henry Madrid
Signature of individual signing on behalf of debtor

Henry Madrid
Printed name

Senior Vice President of Finance of Humanigen, Inc.
Position or relationship to debtor